Compare AYTU & CCG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AYTU | CCG |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | China |
| Employees | N/A | 469 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.4M | 30.8M |
| IPO Year | 2015 | N/A |
| Metric | AYTU | CCG |
|---|---|---|
| Price | $2.18 | $12.50 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 1 |
| Target Price | $9.33 | ★ $350.00 |
| AVG Volume (30 Days) | 20.7K | ★ 135.1K |
| Earning Date | 05-13-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $27,632,080.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $43.75 | $567.38 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 277.47 | N/A |
| 52 Week Low | $1.65 | $0.34 |
| 52 Week High | $3.07 | $16.83 |
| Indicator | AYTU | CCG |
|---|---|---|
| Relative Strength Index (RSI) | 46.23 | 77.67 |
| Support Level | $2.10 | $0.69 |
| Resistance Level | $2.31 | $16.83 |
| Average True Range (ATR) | 0.05 | 0.87 |
| MACD | -0.00 | 1.22 |
| Stochastic Oscillator | 30.77 | 70.40 |
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
Cheche Group Inc is engaged in the operation of providing insurance transaction services, Software-as-a-Service (SaaS) services, and other services in China. It is China's independent technology-empowered platform for auto insurance transaction services by digital auto insurance transaction premiums and insurance technology companies. The company has reshaped the traditional auto insurance distribution and services value chain to create a digital platform by improving operational efficiencies, reducing transaction costs, and expanding distribution channels. Its business scope ranges from digital insurance transactions, SaaS platforms for insurance intermediaries, AI-driven insurance pricing and underwriting services, auto insurance services for new energy vehicle (NEV) manufacturers, etc.